Merck Is in Advanced Talks to Buy Seagen for Roughly $40 Billion or More - WSJ - The Wall Street Journal

A deal, potentially worth $40 billion or more, would help Merck broaden its lineup of cancer drugs, currently led by Keytruda.

Merck & Co. is in advanced talks to acquire Seagen and is aiming to agree on a purchase of the cancer biotech in the next few weeks, according to people familiar with the matter, in a deal that c… [+280 chars]

full article...